Japan’s Nichi-Iko Pharmaceutical Co., Ltd. has sliced its full-year core operating profit guidance by almost three-quarters just weeks after its financial first quarter closed, reflecting ongoing supply issues at the company’s key Namerikawa plant in the Toyama prefecture.
A core operating profit of just ¥700m ($6.4m) is now anticipated for the firm’s financial year ending in March 2022, down from an initial ¥2